share_log

Both Private Companies Who Control a Good Portion of Sinopharm Group Co. Ltd. (HKG:1099) Along With Institutions Must Be Dismayed After Last Week's 4.1% Decrease

Both Private Companies Who Control a Good Portion of Sinopharm Group Co. Ltd. (HKG:1099) Along With Institutions Must Be Dismayed After Last Week's 4.1% Decrease

两家私营公司都控制着国药集团公司的大部分股份在上周下跌4.1%之后,Ltd.(HKG: 1099)以及机构一定感到沮丧
Simply Wall St ·  2023/05/31 22:33

Key Insights

关键见解

  • Significant control over Sinopharm Group by private companies implies that the general public has more power to influence management and governance-related decisions
  • China National Pharmaceutical Group Corporation owns 57% of the company
  • Institutions own 24% of Sinopharm Group
  • 私营公司对国药集团的重大控制意味着公众拥有更大的权力来影响管理和治理相关决策
  • 中国制药集团公司拥有该公司 57% 的股份
  • 机构拥有国药集团24%的股份

If you want to know who really controls Sinopharm Group Co. Ltd. (HKG:1099), then you'll have to look at the makeup of its share registry. The group holding the most number of shares in the company, around 57% to be precise, is private companies. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

如果你想知道谁真正控制了国药集团公司Ltd.(HKG: 1099),那么你得看看其股票登记处的构成。持有公司股份最多的集团,确切地说约为57%,是私营公司。换句话说,该集团将从对公司的投资中获得最大收益(或损失最大)。

Following a 4.1% decrease in the stock price last week, private companies suffered the most losses, but institutions who own 24% stock also took a hit.

继上周股价下跌4.1%之后,私营公司遭受的损失最大,但拥有24%股票的机构也受到打击。

Let's delve deeper into each type of owner of Sinopharm Group, beginning with the chart below.

让我们从下图开始,更深入地研究国药集团的每种类型的所有者。

Check out our latest analysis for Sinopharm Group

查看我们对国药集团的最新分析

ownership-breakdown
SEHK:1099 Ownership Breakdown June 1st 2023
香港交易所:1099 所有权明细 2023 年 6 月 1 日

What Does The Institutional Ownership Tell Us About Sinopharm Group?

关于国药集团,机构所有权告诉我们什么?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

机构在向自己的投资者报告时通常会根据基准来衡量自己,因此,一旦股票被纳入主要指数,他们通常会对股票更加热情。我们预计大多数公司都会有一些机构在册,尤其是在它们正在成长的情况下。

Sinopharm Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sinopharm Group's historic earnings and revenue below, but keep in mind there's always more to the story.

国药集团已经在股票登记处设立了机构。事实上,他们拥有该公司可观的股份。这意味着在这些机构工作的分析师已经研究了这只股票,他们很喜欢。但是就像其他人一样,他们可能错了。当多家机构拥有一只股票时,总是存在处于 “拥挤交易” 的风险。当这样的交易出错时,多方可能会竞相快速出售股票。在没有增长历史的公司中,这种风险更高。你可以在下面看到国药集团的历史收益和收入,但请记住,故事中总会有更多。

earnings-and-revenue-growth
SEHK:1099 Earnings and Revenue Growth June 1st 2023
SEHK: 1099 2023 年 6 月 1 日收益和收入增长

We note that hedge funds don't have a meaningful investment in Sinopharm Group. China National Pharmaceutical Group Corporation is currently the largest shareholder, with 57% of shares outstanding. This essentially means that they have extensive influence, if not outright control, over the future of the corporation. FMR LLC is the second largest shareholder owning 5.2% of common stock, and Lazard Asset Management LLC holds about 3.0% of the company stock.

我们注意到,对冲基金对国药集团没有有意义的投资。中国制药集团公司目前是最大的股东,已发行股份的57%。这本质上意味着他们对公司的未来具有广泛的影响力,如果不是完全控制的话。FMR LLC是第二大股东,拥有5.2%的普通股,Lazard Asset Management LLC持有该公司约3.0%的股份。

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

研究机构所有权是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪也可以达到同样的目的。有很多分析师在报道该股,因此可能也值得一看他们的预测。

Insider Ownership Of Sinopharm Group

国药集团的内部所有权

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

公司内部人员的定义可能是主观的,并且在不同的司法管辖区之间确实有所不同。我们的数据反映了个人内部人士,至少涵盖了董事会成员。公司管理层对董事会负责,后者应代表股东的利益。值得注意的是,有时高层管理人员自己也是董事会成员。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多数人认为内部所有权是积极的,因为这可能表明董事会与其他股东关系良好。但是,在某些情况下,过多的权力集中在该群体中。

Our data suggests that insiders own under 1% of Sinopharm Group Co. Ltd. in their own names. However, it's possible that insiders might have an indirect interest through a more complex structure. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Though their holding amounts to less than 1%, we can see that board members collectively own HK$4.1m worth of shares (at current prices). Arguably recent buying and selling is just as important to consider. You can click here to see if insiders have been buying or selling.

我们的数据表明,内部人士拥有国药集团公司不到1%的股份。Ltd. 以他们自己的名字。但是,内部人士可能会通过更复杂的结构产生间接利益。这是一家非常大的公司,因此看到内部人士拥有该公司的很大一部分股份会令人惊讶。尽管他们的持股量不到1%,但我们可以看到董事会成员共同拥有价值410万港元的股票(按当前价格计算)。可以说,最近的买入和卖出同样需要考虑。你可以点击这里查看内部人士是否在买入或卖出。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 19% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

包括散户投资者在内的公众拥有该公司19%的股份,因此不容忽视。尽管这种所有权规模可能不足以使政策决定对他们有利,但它们仍然可以对公司政策产生集体影响。

Private Company Ownership

私人公司所有权

Our data indicates that Private Companies hold 57%, of the company's shares. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

我们的数据表明,私人公司持有公司57%的股份。可能值得对此进行更深入的研究。如果关联方,例如内部人士,对其中一家私营公司有兴趣,则应在年度报告中披露。私营公司也可能在公司中拥有战略利益。

Next Steps:

后续步骤:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

我觉得看看究竟是谁拥有一家公司非常有趣。但是,要真正获得见解,我们也需要考虑其他信息。

I always like to check for a history of revenue growth. You can too, by accessing this free chart of historic revenue and earnings in this detailed graph.

我一直喜欢检查一下 收入增长的历史。你也可以,通过访问这张免费的历史收入和收益图表 详细图表

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

如果你想了解分析师对未来增长的预测,千万不要错过这篇文章 免费的 分析师预测报告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章无意提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发